시장보고서
상품코드
1437507

세계 망막 생물학적 제제 시장 : 약제 클래스별, 적응증별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Retinal Biologics Market, By Drug Class, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 322 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

망막생물제제 시장 규모는 2023년 223억 4,500만 달러로 평가되었고 2024년부터 2032년까지 복합 연간 성장률(CAGR) 7.5%로 확대될 전망입니다

망막 생물학적학적 제형 시장 : 시장 역학

당뇨병과 황반변성의 유병률 증가가 시장 수요를 촉진

전 세계적으로 당뇨병과 황반 변성증의 유병률이 증가하고 있으며 예측 기간 동안 망막 생물학적학적 제제 시장을 견인할 것으로 기대되고 있습니다. 예를 들어 당뇨병 연구소 재단이 발표한 데이터에 따르면 미국인의 11.3%, 3,730만 명이 당뇨병을 앓고 있습니다. 2,870만명이 당뇨병으로 진단받을 것으로 예측됩니다. 세계 860만명이 당뇨병을 앓고 있지만, 아직 자신의 증상을 자각하지 않습니다. 마찬가지로 CDC가 제공한 데이터에 따르면 2019년에는 40세 이상의 미국인 1,980만 명(인구의 12.6%)이 연령 황반변성(AMD)을 앓고 있습니다. 따라서 앞서 언급한 통계는 시장의 수익 성장을 가속할 것으로 예상됩니다.

망막 생물학적 제제 시장 : 주요 인사이트력

당사의 리서치 애널리스트가 공유한 분석에 따르면 시장은 예측 기간(2024-2032년)에 약 7.5%의 복합 연간 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

약물 클래스별로는 VEGF-A 길항제가 시장을 독점

적응증별로는 황반변성이 2023년 최대 시장 점유율을 차지

유통 채널별로 병원 약국이 시장을 독점

지역별로는 북미가 2023년 매출액 톱

망막 생물학적 제제 시장 : 세분화 분석 :

망막 생물학적 제제 시장은 약물 클래스별, 적응증별, 유통 채널별, 지역별로 구분됩니다.

시장은 약물 클래스별로 2가지로 분류된다: TNF-a Inhibitor와 VEGF-A Antagonist입니다. VEGF-A 길항제는 시장을 독점합니다. VEGF-A 길항제 부문은 시장을 독점합니다. 예를 들어, 노발티스는 Beovu(R)(브로르시주맙) 주사제가 습성 연령 황반변성(AMD)의 치료제로서 유럽 위원회(EC)로부터 승인되었음을 밝혔습니다. Beovu는 유럽 위원회에 의해 허가된 최초의 항-VEGF 약물이며, 질병 활동성의 중요한 지표인 망막액(IRF/SRF)의 소실률이 아프리베르셉트에 비해 양호하다는 것 가 표시되어 있다(부차 평가 항목).

시장은 적응증별로 당뇨병망막증, 황반변성, 포도막염, 기타 4가지로 분류됩니다. 황반변성은 2023년 최대 시장 점유율을 차지하며, 황반변성용으로 개발되는 약물의 수가 증가하고 있으며, 이 질환 세계 이환율이 증가하고 있기 때문에 예측기간 그중에도 같은 패턴이 계속될 것으로 예상됩니다. 예를 들어, 2022년 9월에 국립의학 도서관이 발표한 조사에서는 2040년까지 세계에서 3억 명 이상이 연령 황반 변성(AMD)을 앓고 있다고 예측됩니다.

이 시장은 유통 채널에 따라 병원 약국, 소매 약국, 온라인 약국의 3개로 분류됩니다. 병원 약국이 시장을 독점하고 있어 다양한 유형의 약제가 입수 가능하기 때문에 예측 기간 동안에도 그 우위성을 유지할 것으로 보입니다.

망막 생물학적 제제 시장 : 지리적 인사이트

지리적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 전개하는 국가에 따라 더 나뉩니다. 북미는 예측 기간 동안 망막 생물학적 제제 시장을 선도할 것으로 예상됩니다. 이 지역의 확대는 주요 시장 기업의 존재와 제품 승인에 기인합니다. 예를 들어(2023년) 8월, 단클론항체인 Veopoz(pozelimab-bbfg)는 Regeneron Pharmaceuticals사에 의해 성인 및 1세 이상의 소아 환자에서 CD55 결핍성 단백질 상실성 장증으로도 알려진 CHAPLE병 치료제 로 FDA에서 승인되었습니다. 또한, 당뇨병성 망막증, 당뇨병성 황반부종, 습성 노화황반변성(wAMD)의 치료제로서 고용량 제제인 아이리어 HD(아플리베르셉트)주 8mg가 FDA로부터 승인되었습니다고 보고했습니다. 또한 당뇨병 및 황반변성의 유병률 증가는 이 지역 시장 성장을 가속할 것으로 예상됩니다.

망막 생물학적 제제 시장 : 경쟁 구도:

시장에서 사업을 전개하는 주요 기업은 F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc., Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb입니다. 새로운 시장에 접근하기 위해 시장 진출기업은 신제품 창출, 자금 조달 및 투자, M&A 및 기타 전략적 제휴 등 다양한 전략적 이니셔티브를 지속적으로 추구하고 있습니다.

목차

제1장 망막 생물학적 제제 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 망막 생물학적 제제의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 망막 생물학적 제제 산업 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀의 분석

제5장 망막 생물학적 제제 시장 : COVID-19 감염증의 영향 분석

  • 신형 코로나 바이러스 감염증 이전의 영향 분석
  • 신형 코로나바이러스 감염증 후의 영향 분석

제6장 망막 생물학적 제제 시장 상황

  • 레티날 생물학적 제제 시장 점유율 분석(2023년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥기업의 분석

제7장 망막 생물학적 제제 시장-약제 클래스별

  • 개요
    • 약물 클래스별 부문 점유율 분석
    • TNF-α 억제제
    • VEGF-A 길항제

제8장 망막 생물학적 제제 시장-적응증별

  • 개요
    • 적응증별 부문 점유율 분석
    • 당뇨병성 망막증
    • 황반 변성증
    • 포도막염
    • 기타

제9장 망막 생물학적 제제 시장-유통 채널별

  • 개요
    • 판매 채널별 부문 점유율 분석
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제10장 망막 생물학적 제제 시장-지역별

  • 소개
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 - 망막 생물학적 제제 산업

  • 경쟁 대시보드
  • 기업 프로파일
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck &Co Inc
    • Bayer AG
    • AbbVie Inc.
    • Janssen Biotech
    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Fresenius SE
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis AG
    • Amgen Inc
    • Regeneron Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb

제12장 애널리스트의 전방위 전망

BJH 24.03.08

REPORT HIGHLIGHT

Retinal Biologics Market size was valued at USD 22,345 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Specialized therapeutic compounds called retinal biologics are used to treat a variety of retinal conditions, including diabetic retinopathy and macular degeneration. These biologics, which include proteins and antibodies produced from living things, are made to specifically target molecules or processes associated with retinal disorders. They provide more effective treatment alternatives than traditional techniques by offering tailored medicines that address the underlying processes of retinal diseases. Usually, intravitreal injections are used to give retinal biologics, which entail injecting the drug right into the eye.

Retinal Biologics Market- Market Dynamics

Increasing prevalence of diabetes and macular degeneration to propel market demand

The increasing prevalence of diabetes and macular degeneration across the globe is expected to drive the retinal biologics market over the forecast period. For instance, according to the data published by the Diabetes Research Institute Foundation, 11.3% of Americans, or 37.3 million individuals, suffer from diabetes. 28.7 million persons were projected to have been diagnosed with diabetes. 8.6 million people worldwide suffer from diabetes but are not yet aware of their condition. Similarly, as per the data provided by the CDC, 19.8 million Americans (or 12.6% of the population) over 40 had age-related macular degeneration (AMD) in 2019. Thus, the aforementioned statistics are expected to propel the revenue growth of the market.

Retinal Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on drug class segmentation, the VEGF-A Antagonist sector dominates the market

Based on indication segmentation, the macular degeneration held the largest market share in 2023

Based on distribution channel segmentation, the hospital pharmacies dominate the market

Based on region, North America was the leading revenue generator in 2023

Retinal Biologics Market- Segmentation Analysis:

The Global Retinal Biologics Market is segmented based on Drug Class, Indication, Distribution Channel, and Region.

The market is divided into two categories based on drug class: TNF-a Inhibitor and VEGF-A Antagonist. The VEGF-A Antagonist sector dominates the market. The segment expansion is attributed to the growing product approvals. For instance, Novartis disclosed that Beovu® (brolucizumab) injection is now authorized by the European Commission (EC) to treat wet age-related macular degeneration (AMD). Beovu is the first anti-VEGF medication licensed by the European Commission that has shown better resolution of retinal fluid (IRF/SRF), a crucial indicator of disease activity, in comparison to aflibercept (secondary endpoints).

The market is divided into four categories based on indication: diabetic retinopathy, macular degeneration, uveitis and others. Macular degeneration held the largest market share in 2023 and is expected to continue the same pattern during the forecast period due to the growing number of drugs being developed for macular degeneration and the condition's increasing global incidence. For instance, in September 2022 research released by the National Library of Medicine predicted that over 300 million people worldwide will have age-related macular degeneration (AMD) by the year 2040.

The market is divided into three categories based on distribution channel: hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies dominate the market and are likely to maintain their dominance during the forecast period due to the availability of various types of medication.

Retinal Biologics Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to lead the retinal biologics market during the forecast period. The regional expansion is attributed to the presence of major market players and the approvals of their products. For instance, in August 2023, Veopoz (pozelimab-bbfg), a monoclonal antibody, was authorized by the FDA by Regeneron Pharmaceuticals to treat CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, in adults and pediatric patients one year of age and older. Additionally, the firm reported that the FDA has authorized Eylea HD (aflibercept) Injection 8 mg, a high-dose form of Eylea, for the treatment of diabetic retinopathy, diabetic macular edema, and wet age-related macular degeneration (wAMD). Furthermore, the increasing prevalence of diabetes and the prevalence of macular degeneration is expected to propel the market growth in the region.

Retinal Biologics Market- Competitive Landscape:

The key players operating in the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc, Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd. and Bristol-Myers Squibb. To obtain access to new markets, market players are continuously pursuing a variety of strategic initiatives, including the creation of new products, funding and investments, mergers and acquisitions, and other strategic partnerships.

Recent Developments:

In June 2023, Wacker Biotech, a contract development and manufacturing organization (CDMO), and Caeregen Therapeutics, a regenerative medicine therapeutics company, will work together to develop and produce CTR-107 (NoregenTM), a novel regenerative therapeutic for the treatment of retinal-related vision loss. To facilitate the start of Phase I/II clinical studies in 2024, Wacker Biotech, as Caeregen's CDMO partner for CTR-107, will create drug substance at its location in Halle, Germany, and complete clinical trial drug product manufacturing at its location in Amsterdam, the Netherlands. The first program to treat familial exudative vitreoretinopathy (FEVR) to get a Rare Pediatric Disease Designation from the US FDA is CTR-107.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINAL BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Merck & Co. Inc

Bayer AG

AbbVie Inc.

Janssen Biotech

Boehringer Ingelheim International GmbH

AstraZeneca plc

Fresenius SE

Teva Pharmaceuticals Industries Ltd.

Novartis AG

Amgen Inc

Regeneron Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • TNF-a Inhibitor
  • VEGF-A Antagonist

GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Diabetic Retinopathy
  • Macular Degeneration
  • Uveitis
  • Others

GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RETINAL BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Retinal Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinal Biologics Market Snippet by Drug Class
    • 2.1.2. Retinal Biologics Market Snippet by Indication
    • 2.1.3. Retinal Biologics Market Snippet by Distribution Channel
    • 2.1.4. Retinal Biologics Market Snippet by Country
    • 2.1.5. Retinal Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinal Biologics Key Market Trends

  • 3.1. Retinal Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinal Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinal Biologics Market Opportunities
  • 3.4. Retinal Biologics Market Future Trends

4. Retinal Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinal Biologics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Retinal Biologics Market Landscape

  • 6.1. Retinal Biologics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinal Biologics Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. TNF-a Inhibitor
    • 7.1.3. VEGF-A Antagonist

8. Retinal Biologics Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Diabetic Retinopathy
    • 8.1.3. Macular Degeneration
    • 8.1.4. Uveitis
    • 8.1.5. Others

9. Retinal Biologics Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Retinal Biologics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Retinal Biologics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Retinal Biologics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Retinal Biologics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Retinal Biologics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Retinal Biologics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Retinal Biologics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co Inc
    • 11.2.4. Bayer AG
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Janssen Biotech
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. AstraZeneca plc
    • 11.2.9. Fresenius SE
    • 11.2.10. Teva Pharmaceuticals Industries Ltd.
    • 11.2.11. Novartis AG
    • 11.2.12. Amgen Inc
    • 11.2.13. Regeneron Pharmaceuticals Inc
    • 11.2.14. Sun Pharmaceutical Industries Ltd.
    • 11.2.15. Bristol-Myers Squibb

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제